Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

34.42 +0.92 (+2.75%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Benzinga Bulls And Bears: T-Mobile, LendingTree, Molina Healthcare — And Trade Deal Optimism Boosts Markets
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
Tesla Posts Downbeat Earnings, Joins Community Health Systems, Chipotle Mexican Grill And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
 
Via Benzinga
Viking Therapeutics Posts Wider Q2 Loss
Via The Motley Fool
Viking Therapeutics Stock Slides After Company Misses Q2 Earnings Estimates
Viking Therapeutics shares fall in Wednesday's after-hours session after the company reported financial results for the second quarter. 
Via Benzinga
Earnings Scheduled For July 23, 2025
 
Via Benzinga
A Look Ahead: Viking Therapeutics's Earnings Forecast
 
Via Benzinga
Viking (VKTX) Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings Intellectual Property
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Viking Therapeutics Inc (NASDAQ:VKTX) Posts Wider Q2 2025 Loss, Shares Drop in After-Hours Trading
Viking Therapeutics reports wider Q2 2025 loss, missing EPS estimates, causing a 5.7% after-hours dip. Focus remains on clinical pipeline progress amid revenue challenges. 
Via Chartmill
Better Growth Buy: Eli Lilly vs. Viking Therapeutics
Via The Motley Fool
3 Monster Stocks in the Making to Buy Right Now
Via The Motley Fool
These 2 Stocks Could More Than Double Your Money, According to Wall Street. Is It Time to Buy?
Via The Motley Fool
After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead.
Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note. 
Via The Motley Fool
Topics Intellectual Property
The Best Stocks to Invest $1,000 In Right Now
Via The Motley Fool
Topics Artificial Intelligence Economy
Better Growth Buy: Eli Lilly vs. Viking Therapeutics
Via The Motley Fool
Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity
Via The Motley Fool
Topics Artificial Intelligence
2 Beaten-Down Stocks With Massive Upside Potential
Via The Motley Fool
10 Incredible Growth Stocks Poised for Long-Term Gains
Via The Motley Fool
Topics Artificial Intelligence
Got $200? 2 Biotech Stocks to Buy and Hold Forever
Via The Motley Fool
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?
The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide. 
Via Investor's Business Daily
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
Timing matters with biotech stocks; these three companies offer distinct risk-reward profiles but have upcoming catalysts that could redefine their value 
Via MarketBeat
Topics Artificial Intelligence Economy
Why This Weight Loss Drug Company's Stock Surged Today
Via The Motley Fool
3 Growth Stocks I'm Loading Up On
Via The Motley Fool
Topics Artificial Intelligence Government
Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In Obesity
The company just initiated two Phase 3 studies of its weekly under-the-skin shot to stoke weight loss. 
Via Investor's Business Daily
What's Going On With Viking Therapeutics Stock On Wednesday?
Viking Therapeutics begins Phase 3 trials for VK2735, testing weekly injections in over 5,000 adults with obesity or type 2 diabetes over 78 weeks. 
Via Benzinga
My 5 Favorite Dirt Cheap Stocks to Buy Right Now
Via The Motley Fool
Topics Artificial Intelligence Economy World Trade
Amgen Expands Development Plans For Highly Anticipated Obesity Drug
Amgen is expanding its plans for weight-loss drug, MariTide, with a trio of upcoming Phase 3 studies. 
Via Investor's Business Daily
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
Via The Motley Fool
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.
Via The Motley Fool
Are These 2 High-Flying Growth Stocks Still Worth Buying After Recent Pullbacks?
Via The Motley Fool
Topics Government
< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.